1. Home
  2. VNRX vs CMMB Comparison

VNRX vs CMMB Comparison

Compare VNRX & CMMB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo VolitionRX Limited

VNRX

VolitionRX Limited

HOLD

Current Price

$0.18

Market Cap

7.2M

Sector

Health Care

ML Signal

HOLD

Logo Chemomab Therapeutics Ltd.

CMMB

Chemomab Therapeutics Ltd.

SELL

Current Price

$1.24

Market Cap

10.2M

Sector

Health Care

ML Signal

SELL

Company Overview

Basic Information
Metric
VNRX
CMMB
Founded
N/A
2004
Country
United States
Israel
Employees
N/A
N/A
Industry
Biotechnology: In Vitro & In Vivo Diagnostic Substances
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
7.2M
10.2M
IPO Year
2012
2023

Fundamental Metrics

Financial Performance
Metric
VNRX
CMMB
Price
$0.18
$1.24
Analyst Decision
Buy
Buy
Analyst Count
5
2
Target Price
$13.62
★ $15.00
AVG Volume (30 Days)
★ 1.9M
133.0K
Earning Date
11-12-2026
11-19-2026
Dividend Yield
N/A
N/A
EPS Growth
38.00
★ 101.67
EPS
N/A
★ 0.04
Revenue
★ $1,727,384.00
N/A
Revenue This Year
$57.67
N/A
Revenue Next Year
$240.52
N/A
P/E Ratio
★ N/A
$34.75
Revenue Growth
★ 40.04
N/A
52 Week Low
$0.13
$1.05
52 Week High
$3.26
$3.50

Technical Indicators

Market Signals
Indicator
VNRX
CMMB
Relative Strength Index (RSI) 21.94 28.38
Support Level $0.14 $1.05
Resistance Level $0.18 $1.89
Average True Range (ATR) 0.02 0.20
MACD 0.01 -0.04
Stochastic Oscillator 1.56 18.65

Price Performance

Historical Comparison
VNRX
CMMB

About VNRX VolitionRX Limited

VolitionRX Ltd is a United States-based epigenetics company that applies its Nucleosomics platform through its subsidiaries to develop simple, easy-to-use, cost-effective blood tests to help diagnose and monitor range of life-altering diseases including some cancers and diseases associated with NETosis. The tests are based on the science of Nucleosomics, which is the practice of identifying and measuring nucleosomes in the bloodstream or other bodily fluid - an indication that disease is present. The company is focused on human diagnostics and monitoring but also has a subsidiary focused on diagnostics and monitoring.

About CMMB Chemomab Therapeutics Ltd.

Chemomab Therapeutics Ltd is a clinical-stage biotechnology company, focusing on the discovery and development of therapeutics for fibrosis-related diseases with large unmet needs. The company's candidate, CM-101, is a monoclonal antibody that targets CCL24 and was shown to interfere with the underlying biology of liver, skin, and lung fibrosis using a novel and differentiated mechanism of action. CM-101 has demonstrated the potential to treat multiple severe and life-threatening fibrotic and inflammatory diseases.

Share on Social Networks: